 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...1112131415161718192021...2425» |
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 17, 2016
P2, N=44, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jan 2015 --> Apr 2017
- Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Enrollment change, Trial primary completion date: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) - Oct 14, 2016
P2, N=25, Recruiting, Sponsor: Fundaci
Trial primary completion date: Jan 2015 --> Apr 2017 Not yet recruiting --> Recruiting | N=10 --> 25 | Trial primary completion date: May 2017 --> May 2019
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Oct 11, 2016
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | N=10 --> 25 | Trial primary completion date: May 2017 --> May 2019 Trial primary completion date: May 2016 --> May 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=340, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, Immune cell: Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma (clinicaltrials.gov) - Oct 11, 2016
P4, N=20, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=45, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: May 2016 --> May 2017
- AST-302 / Aston Sci., EpiThany
Enrollment open, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Sep 15, 2016
P1, N=30, Recruiting, Sponsor: University of Washington
Trial primary completion date: May 2016 --> May 2017 Not yet recruiting --> Recruiting
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Sep 7, 2016
P2, N=210, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting N=150 --> 210
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Aug 24, 2016
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=150 --> 210 Trial primary completion date: Jul 2017 --> Jul 2018
- | biropepimut-S (GL-0817) / Gliknik
New P2 trial: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Aug 21, 2016
P2, N=80, Not yet recruiting, Sponsor: Gliknik Inc.
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Aug 8, 2016
P2, N=150, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Sep 2018 --> Jan 2021
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Sep 2018 --> Jan 2021 Trial primary completion date: Jun 2016 --> Dec 2016
- Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
Trial suspension, IO biomarker: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 1, 2016
P2, N=108, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Suspended
- Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date, Trial primary completion date: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Jul 28, 2016
P2, N=188, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Jul 26, 2016
P1, N=9, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020 Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Enrollment closed, Enrollment change, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Jul 26, 2016
P1, N=16, Active, not recruiting, Sponsor: immatics Biotechnologies GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 16
- |||| Rintega (rindopepimut) / Celldex
Trial completion: ACT III: Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Jul 23, 2016
P2, N=82, Completed, Sponsor: Celldex Therapeutics
Recruiting --> Active, not recruiting | N=20 --> 16 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
New P1 trial: SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study (clinicaltrials.gov) - Jul 21, 2016
P1, N=14, Recruiting, Sponsor: Niigata University Medical & Dental Hospital
- Enrollment open: SPRING: High-Risk Neuroblastoma Chemotherapy Without G-CSF (clinicaltrials.gov) - Jul 20, 2016
P=N/A, N=21, Recruiting, Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, NN1213 / Novo Nordisk
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=4, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Terminated --> Completed
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed Trial primary completion date: May 2017 --> May 2018
- | Leukine (sargramostim) / Partner Therap
Trial initiation date: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Jul 19, 2016
P2, N=30, Recruiting, Sponsor: Sanofi
Trial primary completion date: May 2017 --> May 2018 Initiation date: Mar 2016 --> Jul 2016
- | Trial completion: Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (clinicaltrials.gov) - Jul 18, 2016
P2, N=25, Completed, Sponsor: Beth Israel Deaconess Medical Center
Initiation date: Mar 2016 --> Jul 2016 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
New P2 trial: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Jul 18, 2016
P2, N=80, Recruiting, Sponsor: Niigata University Medical & Dental Hospital
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung (clinicaltrials.gov) - Jul 11, 2016
P2, N=28, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| Leukine (sargramostim) / Partner Therap
Trial initiation date, Trial primary completion date: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Jul 1, 2016
P2, N=165, Not yet recruiting, Sponsor: Sanofi
No longer recruiting --> Completed Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jun 2021 --> Jan 2022
- Sitoiganap (ERC1671) / Epitopoietic Research Corp
Trial primary completion date: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Jun 30, 2016
P2, N=84, Recruiting, Sponsor: Daniela A. Bota
Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jun 2021 --> Jan 2022 Trial primary completion date: Mar 2016 --> Mar 2019
- Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment open, Trial initiation date, Trial primary completion date, IO biomarker: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=108, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Sep 2019 --> Mar 2019
- Leukine (sargramostim) / Partner Therap
Trial initiation date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jun 10, 2016
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Sep 2019 --> Mar 2019 Initiation date: Sep 2015 --> Jun 2014
- New trial: SPRING: High-Risk Neuroblastoma Chemotherapy Without G-CSF (clinicaltrials.gov) - Jun 1, 2016
P=N/A, N=21, Not yet recruiting, Sponsor: Baylor College of Medicine
- | Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - May 24, 2016
P1, N=37, Completed, Sponsor: Howard Gendelman, MD
Initiation date: Sep 2015 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jan 2016
- AST-302 / Aston Sci., EpiThany
New P1 trial, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - May 23, 2016
P1, N=30, Not yet recruiting, Sponsor: University of Washington
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - May 19, 2016
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Enrollment open, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - May 16, 2016
P2, N=27, Recruiting, Sponsor: Robin Kate Kelley
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date, Combination therapy: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - May 11, 2016
P3, N=94, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Apr 2007
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - May 5, 2016
P4, N=200, Recruiting, Sponsor: Mark Hall
Trial primary completion date: Aug 2015 --> Apr 2007 Trial primary completion date: Jun 2016 --> Jun 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: PROPEL: Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD) (clinicaltrials.gov) - May 5, 2016
P=N/A, N=240, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Sep 2016 --> Jun 2017
- Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment open, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - May 4, 2016
P1, N=21, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2016 --> Jun 2017 Suspended --> Recruiting
- Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Apr 22, 2016
P2/3, N=400, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Jun 2017 --> Nov 2021
- |||| Leukine (sargramostim) / Partner Therap
Trial primary completion date, Biopsy: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma (clinicaltrials.gov) - Apr 21, 2016
P3, N=380, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Jun 2017 --> Nov 2021 Trial primary completion date: Mar 2016 --> Mar 2017
- BB-MPI-03 / Benovus Bio
Enrollment closed, Enrollment change: BBMPI03: Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (clinicaltrials.gov) - Apr 19, 2016
P1, N=4, Active, not recruiting, Sponsor: Benovus Bio, Inc.
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting | N=30 --> 4
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial primary completion date: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Apr 15, 2016
P2, N=74, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=30 --> 4 Trial primary completion date: Oct 2015 --> Feb 2019
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Apr 11, 2016
P2, N=150, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Oct 2015 --> Feb 2019 N=42 --> 150
- UV1 / Ultimovacs
Trial primary completion date: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=18, Active, not recruiting, Sponsor: Ultimovacs AS
N=42 --> 150 Trial primary completion date: Mar 2016 --> Jul 2016
- | Leukine (sargramostim) / Partner Therap
New P2 trial: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Apr 6, 2016
P2, N=188, Not yet recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment open: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Mar 18, 2016
P1, N=18, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
New P2 trial, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Mar 9, 2016
P2, N=27, Not yet recruiting, Sponsor: Robin Kate Kelley
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 5, 2016
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Trial primary completion date: Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 5, 2016
P1, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Apr 2017 Completed --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2017
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Phase classification: Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma (clinicaltrials.gov) - Mar 2, 2016
P1, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Completed --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2017 Phase classification: P=N/A --> P1